

Title (en)

MODULATION OF EXCITABLE TISSUE FUNCTION BY PERIPHERALLY ADMINISTERED ERYTHROPOIETIN

Title (de)

MODULATION DER FUNKTION VON ERREGBAREM GEWEBE DURCH PERIPHER VERABREICHTES ERYTHROPOIETIN

Title (fr)

MODULATION DE LA FONCTION D'UN TISSU EXCITABLE PAR ADMINISTRATION PERIPHERIQUE D'UNE ERYTHROPOIETINE

Publication

EP 1171147 A4 20030514 (EN)

Application

EP 00923344 A 20000413

Priority

- US 0010019 W 20000413
- US 29093899 A 19990413
- US 54722000 A 20000411

Abstract (en)

[origin: WO0061164A1] Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.

IPC 1-7

A61K 38/00; A61K 38/18; C07K 14/00; A61K 47/48; A61P 27/00; A61P 25/00; A61P 37/00

IPC 8 full level

A61K 38/00 (2006.01); **A61K 38/18** (2006.01); **A61K 38/22** (2006.01); **A61P 9/00** (2006.01); **A61P 9/02** (2006.01); **A61P 9/10** (2006.01); **A61P 25/16** (2006.01); **A61P 25/22** (2006.01); **A61P 25/28** (2006.01); **A61P 25/32** (2006.01); **A61P 27/02** (2006.01); **A61K 45/06** (2006.01); **A61P 27/06** (2006.01); **A61P 29/00** (2006.01); **A61P 43/00** (2006.01); **C07K 14/00** (2006.01)

CPC (source: EP KR)

A61K 38/1816 (2013.01 - EP); **A61K 38/22** (2013.01 - KR); **A61P 7/00** (2018.01 - EP); **A61P 9/00** (2018.01 - EP); **A61P 9/02** (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 9/12** (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 25/08** (2018.01 - EP); **A61P 25/16** (2018.01 - EP); **A61P 25/22** (2018.01 - EP); **A61P 25/28** (2018.01 - EP); **A61P 25/32** (2018.01 - EP); **A61P 27/00** (2018.01 - EP); **A61P 27/02** (2018.01 - EP); **A61P 27/06** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 37/00** (2018.01 - EP); **A61P 39/00** (2018.01 - EP); **A61P 43/00** (2018.01 - EP)

Citation (search report)

- [XY] WO 9810650 A1 19980319 - UNIV EAST CAROLINA [US], et al
- [E] WO 0035475 A2 20000622 - EHRENREICH HANNELORE [DE], et al
- [X] SAKANAKA M ET AL: "In vivo evidence that erythropoietin protects neurons from ischemic damage", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, April 1998 (1998-04-01), pages 4635 - 4640, XP002142085, ISSN: 0027-8424
- [X] BERNAUDIN M ET AL: "A POTENTIAL ROLE FOR ERYTHROPOIETIN IN FOCAL PERMANENT CEREBRAL ISCHEMIA IN MICE", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, RAVEN PRESS, LTD., NEW YORK, NY, US, no. 19, 1999, pages 643 - 651, XP002945970, ISSN: 0271-678X
- [Y] CAMPANA-WM ET AL.: "Identification of a neurotrophic sequence in erythropoietin", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 1, no. 1, 1998, pages 235 - 241, XP001064780
- [Y] KANG Y-S ET AL: "PHARMACOKINETICS AND SATURABLE BLOOD-BRAIN BARRIER TRANSPORT OF BIOTIN BOUND TO A CONJUGATE OF AVIDIN AND A MONOCLONAL ANTIBODY TO THE TRANSFERRIN RECEPTOR", DRUG METABOLISM AND DISPOSITION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 22, no. 1, 1994, pages 99 - 105, XP002933514, ISSN: 0090-9556
- [Y] PARDRIDGE W M: "CNS DRUG DESIGN BASED ON PRINCIPLES OF BLOOD-BRAIN BARRIER TRANSPORT", JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 70, no. 5, May 1998 (1998-05-01), pages 1782 - 1792, XP000885629, ISSN: 0022-3042
- [A] MARTI H H ET AL: "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", KIDNEY INTERNATIONAL, NEW YORK, NY, US, vol. 51, no. 2, February 1997 (1997-02-01), pages 416 - 418, XP001064793, ISSN: 0085-2538
- [A] FRIDEN P M: "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 46, no. 1-2, 5 May 1997 (1997-05-05), pages 117 - 128, XP004096317, ISSN: 0168-3659

Citation (examination)

- ZHOU QING-HUI ET AL: "Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.", MOLECULAR PHARMACEUTICS 6 DEC 2010 LNKD- PUBMED:20860349, vol. 7, no. 6, 6 December 2010 (2010-12-06), pages 2148 - 2155, ISSN: 1543-8392
- SHI F ET AL: "Biotin uptake and transport across bovine brain microvessel endothelial cell monolayers.", PHARMACEUTICAL RESEARCH FEB 1993 LNKD- PUBMED:8456078, vol. 10, no. 2, February 1993 (1993-02-01), pages 282 - 288, ISSN: 0724-8741
- S. PARK, P. SINKO: "Characterization of Biotin Transport across the Blood-Brain Barrier in Mice and Correlation with In Vitro Data", THE AAPS JOURNAL, vol. 6, no. S1, 2004, Retrieved from the Internet <URL:http://www.aapsj.org/abstracts/AM_2004/AAPS2004-002913.PDF>
- SQUADRITO F ET AL: "Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock.", BRITISH JOURNAL OF PHARMACOLOGY MAY 1999 LNKD- PUBMED:10385249, vol. 127, no. 2, 1 January 1999 (1999-01-01) - May 1999 (1999-05-01), pages 482 - 488, ISSN: 0007-1188
- SØLLING-C ET AL.: "Erythropoietin does not attenuate renal dysfunction or inflammation in a porcine model of endotoxemia.", ACTA ANAESTHESIOL SCAND - PUBLICATON AHEAD OF PRINT, 22 February 2011 (2011-02-22), DOI: 10.1111/J.1399-6576.2011.02396.X.
- HENGEMIHLE J M ET AL: "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice.", PHYSIOLOGY & BEHAVIOR JAN 1996 LNKD- PUBMED:8848475, vol. 59, no. 1, January 1996 (1996-01-01), pages 153 - 156, ISSN: 0031-9384
- MIELKE J G ET AL: "Chloroquine administration in mice increases beta-amyloid immunoreactivity and attenuates kainate-induced blood-brain barrier dysfunction.", NEUROSCIENCE LETTERS 23 MAY 1997 LNKD- PUBMED:9185677, vol. 227, no. 3, 23 May 1997 (1997-05-23), pages 169 - 172, ISSN: 0304-3940

- BELAYEV L ET AL: "Protection against blood-brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study.", BRAIN RESEARCH 23 MAR 1998 LNKD- PUBMED:9518648, vol. 787, no. 2, 23 March 1998 (1998-03-23), pages 277 - 285, ISSN: 0006-8993
- WHALEN M J ET AL: "Blood-brain barrier permeability, neutrophil accumulation and vascular adhesion molecule expression after controlled cortical impact in rats: a preliminary study.", ACTA NEUROCHIRURGICA. SUPPLEMENT 1998 LNKD- PUBMED:9779187, vol. 71, 1998, pages 212 - 214, ISSN: 0065-1419
- PAN W ET AL: "Differential permeability of the BBB in acute EAE: enhanced transport of TNT-alpha.", THE AMERICAN JOURNAL OF PHYSIOLOGY OCT 1996 LNKD- PUBMED:8897850, vol. 271, no. 4 Pt 1, October 1996 (1996-10-01), pages E636 - E642, ISSN: 0002-9513
- MINNERUP-J ET AL.: "EPO for stroke therapy - Is there a future for furtherclinical development?", EXPERIMENTAL & TRANSLATIONAL STROKE MEDICINE, vol. 2, no. 10, DOI: 10.1186/2040-7378-2-10
- CENGIZ K ET AL: "Does erythropoietin cause epilepsy.", NEPHRON 1996 LNKD- PUBMED:8773367, vol. 73, no. 2, 1996, pages 320 - 321, ISSN: 0028-2766
- See also references of WO 0061164A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0061164 A1 20001019; AU 4348700 A 20001114; AU 784550 B2 20060504; BG 106058 A 20021229; BG 65353 B1 20080331; BR 0009737 A 20030114; CA 2383940 A1 20001019; CN 1607957 A 20050420; CN 1607957 B 20121010; CR 6501 A 20040415; CZ 20013695 A3 20020213; EA 004766 B1 20040826; EA 200101073 A1 20021031; EP 1171147 A1 20020116; EP 1171147 A4 20030514; HU P0201598 A2 20020928; HU P0201598 A3 20021028; IL 145895 A0 20020725; IL 145895 A 20100531; IS 6104 A 20011011; JP 2003520194 A 20030702; KR 100883232 B1 20090210; KR 101012932 B1 20110208; KR 20020000874 A 20020105; KR 20070094997 A 20070927; MX PA01010177 A 20040910; NO 20014991 D0 20011012; NO 20014991 L 20011115; NZ 514690 A 20040730; NZ 533098 A 20060428; NZ 545478 A 20080430; NZ 560696 A 20100326; PL 352223 A1 20030811; SK 14412001 A3 20020305; TR 200103785 T2 20020621; TR 200402194 T2 20041021

DOCDB simple family (application)

US 0010019 W 20000413; AU 4348700 A 20000413; BG 10605801 A 20011026; BR 0009737 A 20000413; CA 2383940 A 20000413; CN 00808746 A 20000413; CR 6501 A 20011113; CZ 20013695 A 20000413; EA 200101073 A 20000413; EP 00923344 A 20000413; HU P0201598 A 20000413; IL 14589500 A 20000413; IL 14589501 A 20011011; IS 6104 A 20011011; JP 2000610496 A 20000413; KR 20017013093 A 20011013; KR 20077021154 A 20000413; MX PA01010177 A 20000413; NO 20014991 A 20011012; NZ 51469000 A 20000413; NZ 53309800 A 20000413; NZ 54547800 A 20000413; NZ 56069600 A 20000413; PL 35222300 A 20000413; SK 14412001 A 20000413; TR 200103785 T 20000413; TR 200402194 T 20000413